D Wdavid W Wareham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9255393/publications.pdf

Version: 2024-02-01

102 papers 4,156 citations

35 h-index 123424 61 g-index

104 all docs

104 docs citations

104 times ranked 5546 citing authors

#	Article	IF	CITATIONS
1	Draft Genome Sequence of a Multi-drug Resistant Pseudomonas aeruginosa Producing blaSIM Metallo- \hat{l}^2 -lactamase: London, UK. Journal of Global Antimicrobial Resistance, 2022, , .	2.2	3
2	Hospital outbreak of carbapenem-resistant Enterobacterales associated with a bla OXA-48 plasmid carried mostly by Escherichia coli ST399. Microbial Genomics, 2022, 8, .	2.0	3
3	Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection. JAC-Antimicrobial Resistance, 2021, 3, i21-i24.	2.1	14
4	Polymyxin Bâ€Triggered Assembly of Peptide Hydrogels for Localized and Sustained Release of Combined Antimicrobial Therapy. Advanced Healthcare Materials, 2021, 10, e2101465.	7.6	17
5	Antibiotic Resistance Mechanisms and Their Transmission in Acinetobacter baumannii. Advances in Experimental Medicine and Biology, 2021, 1313, 135-153.	1.6	6
6	Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. Journal of Antimicrobial Chemotherapy, 2020, 75, 135-139.	3.0	4
7	Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections—authors' response. Journal of Antimicrobial Chemotherapy, 2020, 75, 2713-2713.	3.0	11
8	Cefiderocol in the treatment of systemic carbapenemase-producing multidrug-resistant Klebsiella pneumoniae infection. Journal of Global Antimicrobial Resistance, 2020, 23, 338-339.	2.2	6
9	A novel plasmid-mediated polymyxin resistance determinant (mcr-1.8) in Escherichia coli recovered from broiler chickens in Brunei Darussalam. Journal of Antimicrobial Chemotherapy, 2019, 74, 3392-3394.	3.0	6
10	Extended-spectrum \hat{l}^2 -lactamase-producing Escherichia coli in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study. Lancet Infectious Diseases, The, 2019, 19, 1325-1335.	9.1	150
11	Hypermucoviscous polymyxin-resistant Klebsiella pneumoniae from Kolkata, India: Genomic and phenotypic analysis. Journal of Global Antimicrobial Resistance, 2019, 17, 1-2.	2.2	6
12	Pharmacokinetic-pharmacodynamic modelling to investigate <i>in vitro</i> synergy between colistin and fusidic acid against MDR <i>Acinetobacter baumannii</i> Journal of Antimicrobial Chemotherapy, 2019, 74, 961-969.	3.0	6
13	Characterization of a colistin-resistant Avian Pathogenic Escherichia coli ST69 isolate recovered from a broiler chicken in Germany. Journal of Medical Microbiology, 2019, 68, 111-114.	1.8	9
14	Effects of In vivo Emergent Tigecycline Resistance on the Pathogenic Potential of Acinetobacter baumannii. Scientific Reports, 2018, 8, 4234.	3.3	9
15	Direct detection of carbapenem resistance determinants in clinical specimens using immunochromatographic lateral flow devices. Journal of Antimicrobial Chemotherapy, 2018, 73, 1997-1998.	3.0	11
16	Rapid Detection of Carbapenemases in Enterobacteriaceae: Evaluation of the Resist-3 O.K.N. (OXA-48,) Tj ETQq0	0 0 0 ggBT	/Oyerlock 10
17	Cyclic Boronates Inhibit All Classes of \hat{l}^2 -Lactamases. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	94
18	Identification of microorganisms grown on chromogenic media by MALDI-TOF MS. Journal of Microbiological Methods, 2017, 136, 17-20.	1.6	7

#	Article	IF	Citations
19	Draft Genome Sequence of a Canine Isolate of Methicillin-Resistant Staphylococcus haemolyticus. Genome Announcements, $2017, 5, .$	0.8	4
20	Emergence and nosocomial spread of carbapenem-resistant OXA-232-producing Klebsiella pneumoniae in Brunei Darussalam. Journal of Global Antimicrobial Resistance, 2017, 9, 96-99.	2.2	31
21	NMR-filtered virtual screening leads to non-metal chelating metallo-β-lactamase inhibitors. Chemical Science, 2017, 8, 928-937.	7.4	63
22	Draft Genome Sequence of Staphylococcus cohnii subsp. <i>urealyticus</i> Isolated from a Healthy Dog. Genome Announcements, 2017, 5, .	0.8	6
23	Draft Genome Sequence of a Multidrug-Resistant Sequence Type 231 Outbreak-Associated Clone of Klebsiella pneumoniae, KP41-2015, Producing OXA-232 Carbapenemase. Genome Announcements, 2017, 5, .	0.8	3
24	In vitro and In vivo Activity of Theaflavin–Epicatechin Combinations versus Multidrug-Resistant Acinetobacter baumannii. Infectious Diseases and Therapy, 2017, 6, 435-442.	4.0	25
25	Draft Genome Sequence of Providencia stuartii PS71, a Multidrug-Resistant Strain Associated with Nosocomial Infections in Greece. Genome Announcements, 2017, 5, .	0.8	3
26	Pentamidine: a drug to consider re-purposing in the targeted treatment of multi-drug resistant bacterial infections?. Journal of Laboratory and Precision Medicine, 2017, 2, 49-49.	1.1	2
27	CHROMagar COL-APSE: a selective bacterial culture medium for the isolation and differentiation of colistin-resistant Gram-negative pathogens. Journal of Medical Microbiology, 2017, 66, 1554-1561.	1.8	39
28	<i>Providencia stuartii</i> lsolates from Greece: Co-Carriage of Cephalosporin (<i>bla</i> _{SHV-5} , <i>bla</i> _{VEB-1}), Carbapenem (<i>bla</i> _{VIM-1}), and Aminoglycoside (<i>rmtB</i>) Resistance Determinants by a Multidrug-Resistant Outbreak Clone. Microbial Drug Resistance, 2016, 22, 379-386.	2.0	24
29	Synergy between Colistin and the Signal Peptidase Inhibitor MD3 Is Dependent on the Mechanism of Colistin Resistance in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2016, 60, 4375-4379.	3.2	6
30	In Vitro Antibacterial Activity of Curcumin–Polymyxin B Combinations against Multidrug-Resistant Bacteria Associated with Traumatic Wound Infections. Journal of Natural Products, 2016, 79, 1702-1706.	3.0	55
31	ESBL-producing Enterobacteriaceae in 24 neonatal units and associated networks in the south of England: no clustering of ESBL-producing <i>Escherichia coli</i> in units or networks: TableÂ1 Journal of Antimicrobial Chemotherapy, 2016, 71, 1174-1177.	3.0	4
32	Rifaximin combined with polymyxins: A potential regimen for selective decontamination of multidrug-resistant bacteria in the digestive tract?. Journal of Global Antimicrobial Resistance, 2016, 4, 11-15.	2.2	3
33	Evaluation of an Immunochromatographic Lateral Flow Assay (OXA-48 <i>K</i> -SeT) for Rapid Detection of OXA-48-Like Carbapenemases in Enterobacteriaceae. Journal of Clinical Microbiology, 2016, 54, 471-473.	3.9	44
34	<i>In vitro</i> and <i>in vivo</i> activity of ML302F: a thioenolate inhibitor of VIM-subfamily metallo β-lactamases. MedChemComm, 2016, 7, 190-193.	3.4	9
35	Colistin and Fusidic Acid, a Novel Potent Synergistic Combination for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections. Antimicrobial Agents and Chemotherapy, 2015, 59, 4544-4550.	3.2	31
36	Comparative virulence of urinary and bloodstream isolates of extra-intestinal pathogenic <i>Escherichia coli</i> i>in a <i>Galleria mellonella</i> model. Virulence, 2015, 6, 145-151.	4.4	50

#	Article	IF	CITATIONS
37	Biochemical characterization of New Delhi metallo- \hat{l}^2 -lactamase variants reveals differences in protein stability. Journal of Antimicrobial Chemotherapy, 2015, 70, 463-469.	3.0	57
38	<i>In Vitro</i> Activity of Epigallocatechin Gallate and Quercetin Alone and in Combination versus Clinical Isolates of Methicillin-Resistant <i>Staphylococcus aureus</i> Journal of Natural Products, 2015, 78, 2145-2148.	3.0	36
39	Deletions in a ribosomal protein-coding gene are associated with tigecycline resistance in Enterococcus faecium. International Journal of Antimicrobial Agents, 2015, 46, 572-575.	2.5	32
40	<i>In Vitro</i> and <i>In Vivo</i> Activities of Tigecycline-Colistin Combination Therapies against Carbapenem-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2014, 58, 3541-3546.	3.2	50
41	Whiter, brighter, and more stable cellulose paper coated with antibacterial carboxymethyl starch stabilized ZnO nanoparticles. Journal of Materials Chemistry B, 2014, 2, 3057-3064.	5.8	37
42	Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin. Journal of Antimicrobial Chemotherapy, 2014, 69, 3236-3243.	3.0	15
43	Carbapenemase-producing Enterobacteriaceae and non-Enterobacteriaceae from animals and the environment: an emerging public health risk of our own making?. Journal of Antimicrobial Chemotherapy, 2014, 69, 287-291.	3.0	210
44	In vitro activity of curcumin in combination with epigallocatechin gallate (EGCG) versus multidrug-resistant Acinetobacter baumannii. BMC Microbiology, 2014, 14, 172.	3.3	84
45	Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1565-1572.	2.9	43
46	In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens. International Journal of Antimicrobial Agents, 2013, 42, 343-346.	2.5	25
47	In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. International Journal of Antimicrobial Agents, 2013, 41, 285-287.	2.5	42
48	In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1291-1294.	2.9	24
49	Evaluation of three selective chromogenic media, CHROMagar ESBL, CHROMagar CTX-M and CHROMagar KPC, for the detection ofKlebsiella pneumoniaeproducing OXA-48 carbapenemase: TableÂ1. Journal of Clinical Pathology, 2013, 66, 348-350.	2.0	27
50	Antifungal Synergy of Theaflavin and Epicatechin Combinations Against Candida albicans. Journal of Microbiology and Biotechnology, 2013, 23, 1322-1326.	2.1	24
51	Association of Extended-Spectrum β-Lactamase VEB-5 and 16S rRNA Methyltransferase ArmA in Salmonella enterica from the United Kingdom. Antimicrobial Agents and Chemotherapy, 2012, 56, 4985-4987.	3.2	8
52	<i>In Vitro</i> Activity of Telavancin in Combination with Colistin versus Gram-Negative Bacterial Pathogens. Antimicrobial Agents and Chemotherapy, 2012, 56, 3080-3085.	3.2	56
53	A Simple, Semiselective Medium for Anaerobic Isolation of Anginosus Group Streptococci from Patients with Chronic Lung Disease. Journal of Clinical Microbiology, 2012, 50, 1430-1432.	3.9	16
54	Two new variants of and creation of a repository for Stenotrophomonas maltophilia quinolone protection protein (Smqnr) genes. International Journal of Antimicrobial Agents, 2011, 37, 89-90.	2.5	9

#	Article	IF	Citations
55	Epidemiology, antibiotic resistance trends and the cost of enteric fever in East London, 2005–2010. Travel Medicine and Infectious Disease, 2011, 9, 206-212.	3.0	18
56	Evaluation of rapid E test MIC testing using CHROM agar on lower respiratory tract samples; collected from ICU from patients with suspected Ventilator associated pneumonia. Journal of Infection, 2011, 63, e22-e23.	3.3	0
57	Modifications to CHROMagar Acinetobacter for improved selective growth of multi-drug resistant Acinetobacter baumannii. Journal of Clinical Pathology, 2011, 64, 164-167.	2.0	18
58	Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. Journal of Antimicrobial Chemotherapy, 2011, 66, 1499-1503.	3.0	96
59	<i>In Vivo</i> Efficacy of Glycopeptide-Colistin Combination Therapies in a <i>Galleria mellonella</i> Model of <i>Acinetobacter baumannii</i> Infection. Antimicrobial Agents and Chemotherapy, 2011, 55, 3534-3537.	3.2	113
60	A Novel Variant, NDM-5, of the New Delhi Metallo- \hat{l}^2 -Lactamase in a Multidrug-Resistant Escherichia coli ST648 Isolate Recovered from a Patient in the United Kingdom. Antimicrobial Agents and Chemotherapy, 2011, 55, 5952-5954.	3.2	312
61	Polymicrobial necrotizing fasciitis involving enterobacteria producing CTX-M-15 extended-spectrum \hat{l}^2 -lactamases. Journal of Medical Microbiology, 2011, 60, 135-137.	1.8	8
62	In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2011, 66, 1047-1051.	3.0	74
63	Prevalence, nucleotide sequence and expression studies of two proteins of a 5.6kb, Class III, Bacteroides plasmid frequently found in clinical isolates from European countries. Plasmid, 2010, 63, 86-97.	1.4	13
64	Infections associated with implanted medical devices. , 2010, , 538-555.		2
65	Effect of the dried residues of two hand gels on the survival of meticillin-resistant Staphylococcus aureus and Acinetobacter calcoaceticus-baumannii. Journal of Infection Prevention, 2010, 11, 70-72.	0.9	3
66	Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia. Journal of Antimicrobial Chemotherapy, 2010, 65, 483-489.	3.0	42
67	AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2010, 65, 1589-1593.	3.0	129
68	Antimicrobial activity of the green tea polyphenol (â^')-epigallocatechin-3-gallate (EGCG) against clinical isolates of Stenotrophomonas maltophilia. International Journal of Antimicrobial Agents, 2010, 36, 129-131.	2.5	115
69	Allele-specific polymerase chain reaction (PCR) for rapid detection of the $aac(6\$^2)$ -lb-cr quinolone resistance gene. International Journal of Antimicrobial Agents, 2010, 36, 476-477.	2.5	23
70	Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. International Journal of Antimicrobial Agents, 2010, 35, 219-226.	2.5	280
71	Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of <i>Acinetobacter baumannii</i> Chemotherapy, 2010, 54, 5316-5322.	3.2	170
72	Evaluation of CHROMagar <i>Acinetobacter</i> for Detection of Enteric Carriage of Multidrug-Resistant <i>Acinetobacter baumannii</i> in Samples from Critically III Patients. Journal of Clinical Microbiology, 2009, 47, 2249-2251.	3.9	38

#	Article	IF	CITATIONS
73	Failure of the MicroScan WalkAway System To Detect Heteroresistance to Carbapenems in a Patient with <i>Enterobacter aerogenes</i> Bacteremia. Journal of Clinical Microbiology, 2009, 47, 3024-3025.	3.9	12
74	A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. Journal of Antimicrobial Chemotherapy, 2009, 63, 775-780.	3.0	122
75	Reduced susceptibility of multidrug-resistant Acinetobacter baumannii to tigecycline in combination with 1-(1-naphthylmethyl)-piperazine is not a pH-dependent phenomenon. Journal of Antimicrobial Chemotherapy, 2009, 63, 1075-1076.	3.0	О
76	Prevention of an outbreak of nosocomial bloodstream infection associated with a new vascular access device by retraining of staff. Journal of Hospital Infection, 2009, 72, 85-87.	2.9	2
77	Plasmid-mediated quinolone resistance genes in Enterobacteriaceae isolates associated with community and nosocomial urinary tract infection in East London, UK. International Journal of Antimicrobial Agents, 2009, 34, 490-491.	2.5	13
78	Pancreatitis, Diarrhea, and Glycopeptide Dependence. Infectious Diseases in Clinical Practice, 2009, 17, 206-207.	0.3	O
79	Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 607-612.	2.9	100
80	Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005 – 2006. Annals of Clinical Microbiology and Antimicrobials, 2008, 7, 13.	3.8	123
81	A case of febrile neutropenia with a skin rash. Journal of Infection, 2008, 56, 309.	3.3	O
82	Tackling antibiotic resistance: a dose of common antisense?. Journal of Antimicrobial Chemotherapy, 2008, 63, 225-229.	3.0	56
83	Paradoxical effect of 1-(1-naphthylmethyl)-piperazine on resistance to tetracyclines in multidrug-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2008, 63, 349-352.	3.0	16
84	Low concentrations of commercial alcohol hand rubs facilitate growth of and secretion of extracellular proteins by multidrug-resistant strains of Acinetobacter baumannii. Journal of Medical Microbiology, 2007, 56, 1595-1599.	1.8	30
85	A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates. International Journal of Medical Microbiology, 2007, 297, 227-234.	3.6	40
86	Herpes zoster. BMJ: British Medical Journal, 2007, 334, 1211-1215.	2.3	110
87	Genetic analysis of mechanisms of multidrug resistance in a clinical isolate of Bacteroides fragilis. Clinical Microbiology and Infection, 2007, 13, 183-189.	6.0	53
88	In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Annals of Clinical Microbiology and Antimicrobials, 2006, 5, 10.	3.8	52
89	Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. Journal of Infection, 2006, 52, 300-304.	3.3	34
90	In Vitro Activities of Polymyxin B, Imipenem, and Rifampin against Multidrug-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2006, 50, 825-826.	3.2	14

#	Article	IF	CITATIONS
91	Listeriosis Due to Infection with a Catalase-Negative Strain of Listeria monocytogenes. Journal of Clinical Microbiology, 2006, 44, 1917-1918.	3.9	15
92	The dangers of dog bites. Journal of Clinical Pathology, 2006, 60, 328-329.	2.0	19
93	ThePseudomonas aeruginosaPA14 type III secretion system is expressed but not essential to virulence in theCaenorhabditis elegans–P. aeruginosapathogenicity model. FEMS Microbiology Letters, 2005, 242, 209-216.	1.8	22
94	Advances in bacterial specific imaging. Brazilian Archives of Biology and Technology, 2005, 48, 145-152.	0.5	27
95	Chloramphenicol in the 21st century. British Journal of Hospital Medicine, 2002, 63, 157-161.	0.2	24
96	Imaging bacterial infection with 99mTc-ciprofloxacin (Infecton). Journal of Clinical Pathology, 2002, 55, 817-823.	2.0	148
97	Infection imaging with radiopharmaceuticals in the 21st century. Brazilian Archives of Biology and Technology, 2002, 45, 25-37.	0.5	51
98	Concerns about 99mTc-labelled ciprofloxacin for infection detection. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 779-781.	2.1	8
99	Pneumonitis in an elderly Bangladeshi man. Journal of Clinical Pathology, 2001, 54, 494-494.	2.0	2
100	Glanders in a Military Research Microbiologist. New England Journal of Medicine, 2001, 345, 1644-1644.	27.0	4
101	Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1865-1866.	2.1	8
102	Concerns about 99mTc-labelled ciprofloxacin for infection detection. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1866-1866.	2.1	8